Loading...
Motilal Oswal S&P BSE Healthcare ETF
EquitySector - HealthcareVery High Risk
NAV (23-Oct-25)
₹45.75-0.11%1D
Returns (Since Inception)
23.84%
Rated ★4.3+ on 
Fund Overview
Fund Size
₹33 Cr
Expense Ratio
0.23%
ISIN
INF247L01BB1
Minimum SIP
-
Exit Load
-
Inception Date
29 Jul 2022
About this fund
Motilal Oswal S&P BSE Healthcare ETF is a Sector - Healthcare mutual fund schemes offered by Motilal Oswal Mutual Fund. This fund has been in existence for 3 years, 2 months and 25 days, having been launched on 29-Jul-22.
As of 23-Oct-25, it has a Net Asset Value (NAV) of ₹45.75, Assets Under Management (AUM) of 32.76 Crores, and an expense ratio of 0.23%.
As of 23-Oct-25, it has a Net Asset Value (NAV) of ₹45.75, Assets Under Management (AUM) of 32.76 Crores, and an expense ratio of 0.23%.
- Motilal Oswal S&P BSE Healthcare ETF has given a CAGR return of 23.84% since inception.
- The fund's asset allocation comprises around 99.85% in equities, 0.00% in debts, and 0.15% in cash & cash equivalents.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+6.20%
+1.30% (Cat Avg.)
3 Years
+25.00%
+23.05% (Cat Avg.)
Since Inception
+23.84%
— (Cat Avg.)
Portfolio Summaryas of 30th September 2025
| Equity | ₹32.71 Cr | 99.85% |
| Others | ₹0.05 Cr | 0.15% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹4.19 Cr | 12.78% |
| Cipla Ltd | Equity | ₹2.08 Cr | 6.35% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹2.05 Cr | 6.26% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹1.85 Cr | 5.66% |
| Dr Reddy's Laboratories Ltd | Equity | ₹1.85 Cr | 5.66% |
| Divi's Laboratories Ltd | Equity | ₹1.8 Cr | 5.50% |
| Fortis Healthcare Ltd | Equity | ₹1.26 Cr | 3.84% |
| Lupin Ltd | Equity | ₹1.15 Cr | 3.51% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.94 Cr | 2.87% |
| Laurus Labs Ltd | Equity | ₹0.81 Cr | 2.48% |
| Alkem Laboratories Ltd | Equity | ₹0.76 Cr | 2.31% |
| Aurobindo Pharma Ltd | Equity | ₹0.75 Cr | 2.29% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.73 Cr | 2.22% |
| Mankind Pharma Ltd | Equity | ₹0.68 Cr | 2.06% |
| Zydus Lifesciences Ltd | Equity | ₹0.61 Cr | 1.87% |
| Biocon Ltd | Equity | ₹0.51 Cr | 1.56% |
| Ipca Laboratories Ltd | Equity | ₹0.47 Cr | 1.42% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.42 Cr | 1.30% |
| Gland Pharma Ltd | Equity | ₹0.39 Cr | 1.20% |
| Abbott India Ltd | Equity | ₹0.37 Cr | 1.14% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.35 Cr | 1.06% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.35 Cr | 1.05% |
| Neuland Laboratories Ltd | Equity | ₹0.31 Cr | 0.96% |
| Wockhardt Ltd | Equity | ₹0.31 Cr | 0.95% |
| Syngene International Ltd | Equity | ₹0.29 Cr | 0.90% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.29 Cr | 0.89% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.29 Cr | 0.89% |
| Piramal Pharma Ltd | Equity | ₹0.29 Cr | 0.89% |
| Cohance Lifesciences Ltd | Equity | ₹0.28 Cr | 0.84% |
| Global Health Ltd | Equity | ₹0.27 Cr | 0.83% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.27 Cr | 0.82% |
| Ajanta Pharma Ltd | Equity | ₹0.25 Cr | 0.78% |
| OneSource Specialty Pharma Ltd | Equity | ₹0.25 Cr | 0.75% |
| Jubilant Pharmova Ltd | Equity | ₹0.22 Cr | 0.66% |
| Sai Life Sciences Ltd | Equity | ₹0.21 Cr | 0.65% |
| Pfizer Ltd | Equity | ₹0.19 Cr | 0.58% |
| Granules India Ltd | Equity | ₹0.19 Cr | 0.57% |
| Poly Medicure Ltd | Equity | ₹0.19 Cr | 0.57% |
| Natco Pharma Ltd | Equity | ₹0.18 Cr | 0.54% |
| Acutaas Chemicals Ltd | Equity | ₹0.17 Cr | 0.52% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.17 Cr | 0.51% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.16 Cr | 0.49% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.14 Cr | 0.43% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.14 Cr | 0.43% |
| Indegene Ltd | Equity | ₹0.14 Cr | 0.43% |
| Concord Biotech Ltd | Equity | ₹0.14 Cr | 0.42% |
| Strides Pharma Science Ltd | Equity | ₹0.13 Cr | 0.41% |
| Metropolis Healthcare Ltd | Equity | ₹0.13 Cr | 0.40% |
| Procter & Gamble Health Ltd | Equity | ₹0.13 Cr | 0.38% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.12 Cr | 0.38% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.12 Cr | 0.37% |
| Aarti Pharmalabs Ltd | Equity | ₹0.1 Cr | 0.32% |
| Sanofi India Ltd | Equity | ₹0.1 Cr | 0.32% |
| Shilpa Medicare Ltd | Equity | ₹0.1 Cr | 0.31% |
| Caplin Point Laboratories Ltd | Equity | ₹0.1 Cr | 0.29% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹0.1 Cr | 0.29% |
| Marksans Pharma Ltd | Equity | ₹0.09 Cr | 0.27% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.08 Cr | 0.25% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹0.08 Cr | 0.24% |
| Emcure Pharmaceuticals Ltd | Equity | ₹0.08 Cr | 0.24% |
| Alivus Life Sciences Ltd | Equity | ₹0.07 Cr | 0.22% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.07 Cr | 0.22% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.07 Cr | 0.21% |
| Sequent Scientific Ltd | Equity | ₹0.05 Cr | 0.17% |
| FDC Ltd | Equity | ₹0.05 Cr | 0.16% |
| Net Receivables / (Payables) | Cash | ₹0.05 Cr | 0.15% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.05 Cr | 0.15% |
| Supriya Lifescience Ltd | Equity | ₹0.05 Cr | 0.14% |
| Senores Pharmaceuticals Ltd | Equity | ₹0.05 Cr | 0.14% |
| Thyrocare Technologies Ltd | Equity | ₹0.04 Cr | 0.14% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.04 Cr | 0.13% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.04 Cr | 0.13% |
| Aarti Drugs Ltd | Equity | ₹0.04 Cr | 0.13% |
| Morepen Laboratories Ltd | Equity | ₹0.04 Cr | 0.13% |
| Blue Jet Healthcare Ltd | Equity | ₹0.04 Cr | 0.12% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.04 Cr | 0.12% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.03 Cr | 0.10% |
| Innova Captab Ltd | Equity | ₹0.03 Cr | 0.10% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.03 Cr | 0.10% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.03 Cr | 0.09% |
| Suven Life Sciences Ltd | Equity | ₹0.03 Cr | 0.09% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹0.03 Cr | 0.09% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.03 Cr | 0.09% |
| Fischer Medical Ventures Ltd | Equity | ₹0.03 Cr | 0.09% |
| Indoco Remedies Ltd | Equity | ₹0.03 Cr | 0.08% |
| Orchid Pharma Ltd | Equity | ₹0.03 Cr | 0.08% |
| Vimta Labs Ltd | Equity | ₹0.03 Cr | 0.08% |
| Bliss GVS Pharma Ltd | Equity | ₹0.02 Cr | 0.08% |
| Gufic Biosciences Ltd | Equity | ₹0.02 Cr | 0.07% |
| RPG Life Sciences Ltd | Equity | ₹0.02 Cr | 0.07% |
| Unichem Laboratories Ltd | Equity | ₹0.02 Cr | 0.07% |
| Hikal Ltd | Equity | ₹0.02 Cr | 0.07% |
| Syncom Formulation (India) Ltd | Equity | ₹0.02 Cr | 0.06% |
| Hester Biosciences Ltd | Equity | ₹0.02 Cr | 0.05% |
| Windlas Biotech Ltd | Equity | ₹0.02 Cr | 0.05% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.05% |
| Shalby Ltd | Equity | ₹0.02 Cr | 0.05% |
| Sigachi Industries Ltd | Equity | ₹0.02 Cr | 0.05% |
| 3B BlackBio Dx Ltd | Equity | ₹0.02 Cr | 0.05% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.05% |
| Panacea Biotec Ltd | Equity | ₹0.02 Cr | 0.05% |
| Suraksha Diagnostic Ltd | Equity | ₹0.01 Cr | 0.04% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹0.01 Cr | 0.04% |
| Novartis India Ltd | Equity | ₹0.01 Cr | 0.04% |
| Laxmi Dental Ltd | Equity | ₹0.01 Cr | 0.04% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.04% |
| Wanbury Ltd | Equity | ₹0.01 Cr | 0.04% |
| Kopran Ltd | Equity | ₹0.01 Cr | 0.04% |
| Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.04% |
| Bajaj Healthcare Ltd | Equity | ₹0.01 Cr | 0.03% |
| Jagsonpal Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.03% |
| Kwality Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.03% |
| GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.03% |
| Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.03% |
| Fermenta Biotech Ltd | Equity | ₹0.01 Cr | 0.02% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0.01 Cr | 0.02% |
| Anuh Pharma Ltd Shs Dematerialised | Equity | ₹0.01 Cr | 0.02% |
| Sastasundar Ventures Ltd | Equity | ₹0.01 Cr | 0.02% |
| Nectar Lifesciences Ltd | Equity | ₹0 Cr | 0.01% |
| Shree Ganesh Remedies Ltd Ordinary Shares | Equity | ₹0 Cr | 0.01% |
Allocation By Market Cap (Equity)
Large Cap Stocks
52.51%
Mid Cap Stocks
20.57%
Small Cap Stocks
26.77%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹32.5 Cr | 99.22% |
| Basic Materials | ₹0.21 Cr | 0.63% |
Risk & Performance Ratios
Standard Deviation
This fund
16.21%
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
0.97
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better
Fund Managers
Additional Scheme Detailsas of 30th September 2025
ISIN INF247L01BB1 | Expense Ratio 0.23% | Exit Load - | Fund Size ₹33 Cr | Age 3 years 2 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
About the AMC
Motilal Oswal Mutual Fund
Total AUM
₹1,27,741 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Other Funds by Motilal Oswal Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Take control of your wealth
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Motilal Oswal S&P BSE Healthcare ETF?
The NAV of Motilal Oswal S&P BSE Healthcare ETF, as of 23-Oct-2025, is ₹45.75.
What are the returns of Motilal Oswal S&P BSE Healthcare ETF?
The fund has generated 6.20% over the last 1 year and 25.00% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.
What is the portfolio composition of Motilal Oswal S&P BSE Healthcare ETF?
The fund's allocation of assets is distributed as 99.85% in equities, 0.00% in bonds, and 0.15% in cash and cash equivalents.
Who manages the Motilal Oswal S&P BSE Healthcare ETF?
The fund managers responsible for Motilal Oswal S&P BSE Healthcare ETF are:-
- Swapnil Mayekar
- Rakesh Shetty
- Dishant Mehta
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Motilal Oswal S&P BSE Healthcare ETF
EquitySector - HealthcareVery High Risk
NAV (23-Oct-25)
₹45.75-0.11%1D
Returns (Since Inception)
23.84%
Rated ★4.3+ on
Fund Overview
Fund Size
₹33 Cr
Expense Ratio
0.23%
ISIN
INF247L01BB1
Minimum SIP
-
Exit Load
-
Inception Date
29 Jul 2022
Risk Level
Your principal amount will be at Very High Risk
About this fund
Motilal Oswal S&P BSE Healthcare ETF is a Sector - Healthcare mutual fund schemes offered by Motilal Oswal Mutual Fund. This fund has been in existence for 3 years, 2 months and 25 days, having been launched on 29-Jul-22.
As of 23-Oct-25, it has a Net Asset Value (NAV) of ₹45.75, Assets Under Management (AUM) of 32.76 Crores, and an expense ratio of 0.23%.
As of 23-Oct-25, it has a Net Asset Value (NAV) of ₹45.75, Assets Under Management (AUM) of 32.76 Crores, and an expense ratio of 0.23%.
- Motilal Oswal S&P BSE Healthcare ETF has given a CAGR return of 23.84% since inception.
- The fund's asset allocation comprises around 99.85% in equities, 0.00% in debts, and 0.15% in cash & cash equivalents.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+6.20%
+1.30% (Cat Avg.)
3 Years
+25.00%
+23.05% (Cat Avg.)
Since Inception
+23.84%
— (Cat Avg.)
Portfolio Summaryas of 30th September 2025
| Equity | ₹32.71 Cr | 99.85% |
| Others | ₹0.05 Cr | 0.15% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹4.19 Cr | 12.78% |
| Cipla Ltd | Equity | ₹2.08 Cr | 6.35% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹2.05 Cr | 6.26% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹1.85 Cr | 5.66% |
| Dr Reddy's Laboratories Ltd | Equity | ₹1.85 Cr | 5.66% |
| Divi's Laboratories Ltd | Equity | ₹1.8 Cr | 5.50% |
| Fortis Healthcare Ltd | Equity | ₹1.26 Cr | 3.84% |
| Lupin Ltd | Equity | ₹1.15 Cr | 3.51% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.94 Cr | 2.87% |
| Laurus Labs Ltd | Equity | ₹0.81 Cr | 2.48% |
| Alkem Laboratories Ltd | Equity | ₹0.76 Cr | 2.31% |
| Aurobindo Pharma Ltd | Equity | ₹0.75 Cr | 2.29% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.73 Cr | 2.22% |
| Mankind Pharma Ltd | Equity | ₹0.68 Cr | 2.06% |
| Zydus Lifesciences Ltd | Equity | ₹0.61 Cr | 1.87% |
| Biocon Ltd | Equity | ₹0.51 Cr | 1.56% |
| Ipca Laboratories Ltd | Equity | ₹0.47 Cr | 1.42% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.42 Cr | 1.30% |
| Gland Pharma Ltd | Equity | ₹0.39 Cr | 1.20% |
| Abbott India Ltd | Equity | ₹0.37 Cr | 1.14% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.35 Cr | 1.06% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.35 Cr | 1.05% |
| Neuland Laboratories Ltd | Equity | ₹0.31 Cr | 0.96% |
| Wockhardt Ltd | Equity | ₹0.31 Cr | 0.95% |
| Syngene International Ltd | Equity | ₹0.29 Cr | 0.90% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.29 Cr | 0.89% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.29 Cr | 0.89% |
| Piramal Pharma Ltd | Equity | ₹0.29 Cr | 0.89% |
| Cohance Lifesciences Ltd | Equity | ₹0.28 Cr | 0.84% |
| Global Health Ltd | Equity | ₹0.27 Cr | 0.83% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.27 Cr | 0.82% |
| Ajanta Pharma Ltd | Equity | ₹0.25 Cr | 0.78% |
| OneSource Specialty Pharma Ltd | Equity | ₹0.25 Cr | 0.75% |
| Jubilant Pharmova Ltd | Equity | ₹0.22 Cr | 0.66% |
| Sai Life Sciences Ltd | Equity | ₹0.21 Cr | 0.65% |
| Pfizer Ltd | Equity | ₹0.19 Cr | 0.58% |
| Granules India Ltd | Equity | ₹0.19 Cr | 0.57% |
| Poly Medicure Ltd | Equity | ₹0.19 Cr | 0.57% |
| Natco Pharma Ltd | Equity | ₹0.18 Cr | 0.54% |
| Acutaas Chemicals Ltd | Equity | ₹0.17 Cr | 0.52% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.17 Cr | 0.51% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.16 Cr | 0.49% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.14 Cr | 0.43% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.14 Cr | 0.43% |
| Indegene Ltd | Equity | ₹0.14 Cr | 0.43% |
| Concord Biotech Ltd | Equity | ₹0.14 Cr | 0.42% |
| Strides Pharma Science Ltd | Equity | ₹0.13 Cr | 0.41% |
| Metropolis Healthcare Ltd | Equity | ₹0.13 Cr | 0.40% |
| Procter & Gamble Health Ltd | Equity | ₹0.13 Cr | 0.38% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.12 Cr | 0.38% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.12 Cr | 0.37% |
| Aarti Pharmalabs Ltd | Equity | ₹0.1 Cr | 0.32% |
| Sanofi India Ltd | Equity | ₹0.1 Cr | 0.32% |
| Shilpa Medicare Ltd | Equity | ₹0.1 Cr | 0.31% |
| Caplin Point Laboratories Ltd | Equity | ₹0.1 Cr | 0.29% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹0.1 Cr | 0.29% |
| Marksans Pharma Ltd | Equity | ₹0.09 Cr | 0.27% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.08 Cr | 0.25% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹0.08 Cr | 0.24% |
| Emcure Pharmaceuticals Ltd | Equity | ₹0.08 Cr | 0.24% |
| Alivus Life Sciences Ltd | Equity | ₹0.07 Cr | 0.22% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.07 Cr | 0.22% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.07 Cr | 0.21% |
| Sequent Scientific Ltd | Equity | ₹0.05 Cr | 0.17% |
| FDC Ltd | Equity | ₹0.05 Cr | 0.16% |
| Net Receivables / (Payables) | Cash | ₹0.05 Cr | 0.15% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.05 Cr | 0.15% |
| Supriya Lifescience Ltd | Equity | ₹0.05 Cr | 0.14% |
| Senores Pharmaceuticals Ltd | Equity | ₹0.05 Cr | 0.14% |
| Thyrocare Technologies Ltd | Equity | ₹0.04 Cr | 0.14% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.04 Cr | 0.13% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.04 Cr | 0.13% |
| Aarti Drugs Ltd | Equity | ₹0.04 Cr | 0.13% |
| Morepen Laboratories Ltd | Equity | ₹0.04 Cr | 0.13% |
| Blue Jet Healthcare Ltd | Equity | ₹0.04 Cr | 0.12% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.04 Cr | 0.12% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.03 Cr | 0.10% |
| Innova Captab Ltd | Equity | ₹0.03 Cr | 0.10% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.03 Cr | 0.10% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.03 Cr | 0.09% |
| Suven Life Sciences Ltd | Equity | ₹0.03 Cr | 0.09% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹0.03 Cr | 0.09% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.03 Cr | 0.09% |
| Fischer Medical Ventures Ltd | Equity | ₹0.03 Cr | 0.09% |
| Indoco Remedies Ltd | Equity | ₹0.03 Cr | 0.08% |
| Orchid Pharma Ltd | Equity | ₹0.03 Cr | 0.08% |
| Vimta Labs Ltd | Equity | ₹0.03 Cr | 0.08% |
| Bliss GVS Pharma Ltd | Equity | ₹0.02 Cr | 0.08% |
| Gufic Biosciences Ltd | Equity | ₹0.02 Cr | 0.07% |
| RPG Life Sciences Ltd | Equity | ₹0.02 Cr | 0.07% |
| Unichem Laboratories Ltd | Equity | ₹0.02 Cr | 0.07% |
| Hikal Ltd | Equity | ₹0.02 Cr | 0.07% |
| Syncom Formulation (India) Ltd | Equity | ₹0.02 Cr | 0.06% |
| Hester Biosciences Ltd | Equity | ₹0.02 Cr | 0.05% |
| Windlas Biotech Ltd | Equity | ₹0.02 Cr | 0.05% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.05% |
| Shalby Ltd | Equity | ₹0.02 Cr | 0.05% |
| Sigachi Industries Ltd | Equity | ₹0.02 Cr | 0.05% |
| 3B BlackBio Dx Ltd | Equity | ₹0.02 Cr | 0.05% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.05% |
| Panacea Biotec Ltd | Equity | ₹0.02 Cr | 0.05% |
| Suraksha Diagnostic Ltd | Equity | ₹0.01 Cr | 0.04% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹0.01 Cr | 0.04% |
| Novartis India Ltd | Equity | ₹0.01 Cr | 0.04% |
| Laxmi Dental Ltd | Equity | ₹0.01 Cr | 0.04% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.04% |
| Wanbury Ltd | Equity | ₹0.01 Cr | 0.04% |
| Kopran Ltd | Equity | ₹0.01 Cr | 0.04% |
| Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.04% |
| Bajaj Healthcare Ltd | Equity | ₹0.01 Cr | 0.03% |
| Jagsonpal Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.03% |
| Kwality Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.03% |
| GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.03% |
| Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.03% |
| Fermenta Biotech Ltd | Equity | ₹0.01 Cr | 0.02% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0.01 Cr | 0.02% |
| Anuh Pharma Ltd Shs Dematerialised | Equity | ₹0.01 Cr | 0.02% |
| Sastasundar Ventures Ltd | Equity | ₹0.01 Cr | 0.02% |
| Nectar Lifesciences Ltd | Equity | ₹0 Cr | 0.01% |
| Shree Ganesh Remedies Ltd Ordinary Shares | Equity | ₹0 Cr | 0.01% |
Allocation By Market Cap (Equity)
Large Cap Stocks
52.51%
Mid Cap Stocks
20.57%
Small Cap Stocks
26.77%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹32.5 Cr | 99.22% |
| Basic Materials | ₹0.21 Cr | 0.63% |
Risk & Performance Ratios
Standard Deviation
This fund
16.21%
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
0.97
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better
Fund Managers
Additional Scheme Detailsas of 30th September 2025
ISIN INF247L01BB1 | Expense Ratio 0.23% | Exit Load - | Fund Size ₹33 Cr | Age 3 years 2 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
About the AMC
Motilal Oswal Mutual Fund
Total AUM
₹1,27,741 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Other Funds by Motilal Oswal Mutual Fund
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Motilal Oswal S&P BSE Healthcare ETF?
The NAV of Motilal Oswal S&P BSE Healthcare ETF, as of 23-Oct-2025, is ₹45.75.
What are the returns of Motilal Oswal S&P BSE Healthcare ETF?
The fund has generated 6.20% over the last 1 year and 25.00% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.
What is the portfolio composition of Motilal Oswal S&P BSE Healthcare ETF?
The fund's allocation of assets is distributed as 99.85% in equities, 0.00% in bonds, and 0.15% in cash and cash equivalents.
Who manages the Motilal Oswal S&P BSE Healthcare ETF?
The fund managers responsible for Motilal Oswal S&P BSE Healthcare ETF are:-
- Swapnil Mayekar
- Rakesh Shetty
- Dishant Mehta
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
©2021-2025 Dezerv. All Rights Reserved
Dezerv Investments Pvt. Ltd. is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Dezerv Investments Pvt. Ltd. is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Get your portfolio reviewed by experts
